Skip to main content
. 2004 Jun 8;54(1):1–10. doi: 10.1007/s00262-004-0549-1

Table 2.

Novel IFN-α formulations

IFN-α species Molecular characteristics Doses Advantages vs conventional formulation
Pegylated IFN-α-2a (Pegasys) 40-kDa branched polyethylene glycol (PEG) 450-μg weekly administration Allows protracted tumour cell exposure
Improves patient compliance
Reduces toxicity
Pegylated IFN-α-2b (Peg-Intron A) 12-kDa monomethoxy PEG 7.5 μg/kg weekly administration Allows protracted tumour cell exposure
Improves patient compliance
Reduces toxicity